More recently, four transcriptomic subtypes were defined in HR+/HER2- breast cancer, among which the receptor tyrosine kinase (RTK)-driven subtype had poorest outcomes compared to the canonical luminal, immunogenic, and proliferation subtypes (8). Here, ERBB2 is linked to breast cancer.